BLRX - BioLineRx Ltd.

QQQ $ 454.82 $ -0.01 (-0 %)

DIA $ 398.57 $ 5.83 (1.53 %)

SPY $ 530.36 $ 4.59 (0.88 %)

TLT $ 91.26 $ 0.69 (0.77 %)

GLD $ 225.37 $ -1.23 (-0.57 %)

Previous Close

$ 0.7456

Open

$ 0.80

Bid

$ 0.00 x 0

Ask

$ 0.00 x 0

Day's Range

$ 0.75 - $ 0.81

52 Week Range

$ 0.55 - $ 2.53

Volume

386,015

Average Volume

Market Cap

59.39M

Beta (5Y Monthly)

$ 1.40

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type	Report Link
No Data found

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

BioLineRx Announces Multi-Center Phase 1 T...
05/30/2024 11:11:30

HC Wainwright & Co. Reiterates Buy on BioL...
05/29/2024 14:24:02

HC Wainwright & Co. analyst Joseph Pantginis reiterates BioLine Rx (NASDAQ:BLRX) with a Buy and maintains $21 price target.

BioLineRx shares are trading higher. The c...
05/28/2024 11:44:00

BioLineRx Says Cash, Cash Equivalents, And...
05/28/2024 11:06:15

The company says this amount does not include $6.0 million in gross proceeds received from a registered direct offering and a $...

BioLine Rx Q1 2024 GAAP EPS $(0.00) May No...
05/28/2024 11:03:38

BioLineRx Discloses Abstract On Pilot Stud...
05/24/2024 11:02:58

New analysis of biopsy samples demonstrated a significant increase in CD8+ T-cell density in tumors from all 11 patients trea...

BioLineRx To Present Poster On Economic Mo...
05/06/2024 11:03:27

HC Wainwright & Co. Reiterates Buy on BioL...
04/17/2024 17:35:07

HC Wainwright & Co. analyst Joseph Pantginis reiterates BioLine Rx (NASDAQ:BLRX) with a Buy and maintains $21 price target.

BioLineRx Announces Poster Presentation On...
04/17/2024 11:02:12

BioLineRx Has Drawn-down The Second Tranch...
04/10/2024 11:14:19

BioLineRx Announces $6M Registered Direct ...
04/01/2024 13:02:55

BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX) ("BioLineRx" or the "Company"), a commercial stage biopharmaceutical ...

HC Wainwright & Co. Reiterates Buy on BioL...
03/26/2024 16:12:57

HC Wainwright & Co. analyst Joseph Pantginis reiterates BioLine Rx (NASDAQ:BLRX) with a Buy and maintains $21 price target.

BioLine Rx Q4 EPS $(0.15) Beats $(0.22) Es...
03/26/2024 13:28:42

BioLine Rx (NASDAQ:BLRX) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.22) by...

12-health-care-stocks-moving-in-tuesdays-pre-market-session

12 Health Care Stocks Moving In Tuesday's ...
03/26/2024 13:05:52

BioLineRx FY23 Total Revenues $4.8M, EPS $...
03/26/2024 11:02:32

Earnings Scheduled For March 26, 2024
03/26/2024 08:47:27

Companies Reporting Before The Bell • bluebird bio (NASDAQ:BLUE) is likely to report quarterly loss at $0.66 per share on reve...

Earnings Preview For BioLine Rx
03/25/2024 15:02:32

BioLineRx Announces Notice of Allowance fo...
03/04/2024 12:08:04

HC Wainwright & Co. Reiterates Buy on BioL...
02/29/2024 20:36:19

HC Wainwright & Co. analyst Joseph Pantginis reiterates BioLine Rx (NASDAQ:BLRX) with a Buy and maintains $21 price target.

Biolinerx Announced First Patient Dosed In...
02/28/2024 12:14:21